CDT vs. GLYC, CARM, BFRG, MEIP, LPCN, LPTX, OKUR, ONCO, HCWB, and AFMD
Should you be buying Conduit Pharmaceuticals stock or one of its competitors? The main competitors of Conduit Pharmaceuticals include GlycoMimetics (GLYC), Carisma Therapeutics (CARM), Bullfrog AI (BFRG), MEI Pharma (MEIP), Lipocine (LPCN), Leap Therapeutics (LPTX), OnKure Therapeutics (OKUR), Onconetix (ONCO), HCW Biologics (HCWB), and Affimed (AFMD). These companies are all part of the "pharmaceutical products" industry.
Conduit Pharmaceuticals vs.
Conduit Pharmaceuticals (NASDAQ:CDT) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.
Conduit Pharmaceuticals has higher earnings, but lower revenue than GlycoMimetics.
GlycoMimetics received 314 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Conduit Pharmaceuticals an outperform vote while only 58.33% of users gave GlycoMimetics an outperform vote.
GlycoMimetics has a consensus price target of $8.00, indicating a potential upside of 2,835.78%. Given GlycoMimetics' higher probable upside, analysts clearly believe GlycoMimetics is more favorable than Conduit Pharmaceuticals.
Conduit Pharmaceuticals has a beta of 2.29, indicating that its stock price is 129% more volatile than the S&P 500. Comparatively, GlycoMimetics has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500.
3.3% of Conduit Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of GlycoMimetics shares are held by institutional investors. 30.9% of Conduit Pharmaceuticals shares are held by insiders. Comparatively, 8.7% of GlycoMimetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Conduit Pharmaceuticals' return on equity of 0.00% beat GlycoMimetics' return on equity.
In the previous week, Conduit Pharmaceuticals had 1 more articles in the media than GlycoMimetics. MarketBeat recorded 4 mentions for Conduit Pharmaceuticals and 3 mentions for GlycoMimetics. Conduit Pharmaceuticals' average media sentiment score of 0.71 beat GlycoMimetics' score of 0.00 indicating that Conduit Pharmaceuticals is being referred to more favorably in the media.
Summary
Conduit Pharmaceuticals beats GlycoMimetics on 9 of the 14 factors compared between the two stocks.
Get Conduit Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Conduit Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CDT) was last updated on 3/10/2025 by MarketBeat.com Staff
Free CDT Stock Alerts